Development of positron emission tomography β-amyloid plaque imaging agents - Test2 - elhamkhani - TriplyDB

Development of positron emission tomography β-amyloid plaque imaging agents

Development of positron emission tomography β-amyloid plaque imaging agents

http://www.wikidata.org/entity/Q27012742

about

Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging Unfolded Protein Response and Macroautophagy in Alzheimer's, Parkinson's and Prion Diseases Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease Beta-Amyloid Precursor Protein (βAPP) Processing in Alzheimer's Disease (AD) and Age-Related Macular Degeneration (AMD)Ocular indicators of Alzheimer's: exploring disease in the retina Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography The Use of Neuroimaging to Assess Associations Among Diet, Nutrients, Metabolic Syndrome, and Alzheimer's Disease.Near-infrared fluorescent probes for imaging of amyloid plaques in Alzheimer׳s disease Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia PET/SPECT imaging agents for neurodegenerative diseases.Development and screening of contrast agents for in vivo imaging of Parkinson's disease.Characterization of a brain permeant fluorescent molecule and visualization of Aβ parenchymal plaques, using real-time multiphoton imaging in transgenic mice Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer's disease Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease.What amyloid ligands can tell us about molecular polymorphism and disease.A novel method for quantifying peripheral tissue amyloid load by using the radiolabeled amyloidophilic peptide, p5.Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-β.Identification of promethazine as an amyloid-binding molecule using a fluorescence high-throughput assay and MALDI imaging mass spectrometry.Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (Aβ) in Alzheimer's Disease.Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease Progress update: fluid and imaging biomarkers in Alzheimer's disease.Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus.Compounds for imaging amyloid-β deposits in an Alzheimer's brain: a patent review.[(18)F]Florbetaben: a review in β-amyloid PET imaging in cognitive impairment.Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.Molecular pathogenesis of human amyloidosis: Lessons from β2 -microglobulin-related amyloidosis.Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils.Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.Advances in Aβ plaque detection and the value of knowing: overcoming challenges to improving patient outcomes in Alzheimer's disease.Crown ethers attenuate aggregation of amyloid beta of Alzheimer's disease.Evaluation of [11C]TAZA for amyloid β plaque imaging in postmortem human Alzheimer's disease brain region and whole body distribution in rodent PET/CT.Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer's Disease and Related Disorders.Genetic Variants and Related Biomarkers in Sporadic Alzheimer's Disease.Disaggregation-induced fluorescence enhancement of NIAD-4 for the optical imaging of amyloid-β fibrils.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Small-molecule PET Tracers for Imaging Proteinopathies.Diarylethene based fluorescent switchable probes for the detection of amyloid-β pathology in Alzheimer's disease.

P2860

Q26750249-4C78060D-2B73-4256-9998-8A4EE4997B71 Q26773443-885187D7-ED66-4904-8CD9-2513F18CC30B Q27009411-F46D8F8C-FEFD-4B31-AB87-D102A9DB8462 Q27021938-5ED4FD99-92A0-40B2-89C9-0E3AA1E61DB7 Q28078670-856B5A8F-0EB7-42CA-BA70-803080A8E8C6 Q28273817-4101FFCE-2709-4AA7-9E6D-ECF8526A1FE3 Q30996713-2F5D7377-A766-48FD-A3D4-DDA681278AA6 Q31025427-4AFCE4F8-C64F-41E7-9ABD-E9C632C5E607 Q33727909-AE724DC7-0742-4CC3-BB50-A78599AD240E Q34156602-DEF4018E-D26D-45F4-A929-D9B6A302040D Q34691754-69F998D1-C679-4053-B7B0-033E98DA3129 Q35213005-92E7ABD6-6E20-4A1F-A172-F4F0DCEFB606 Q35639988-594102A4-33ED-4CB0-92EB-058841019053 Q35772537-A1B38B90-0AC1-4E48-BFCB-2B307B297F4D Q35905536-184077CE-D02A-4063-A0AD-239DD24E649E Q35946092-7335D41F-3E18-4FC0-AAB4-3F4A606FDCE4 Q36871202-BB3C5A61-482B-4AE6-979F-73DD3DABDF42 Q37010197-3E5C9C56-F1C4-4B2C-9DB4-9F51D979DC7C Q37104887-CE93FC1A-BB72-4F17-B941-E315C1CA4694 Q37185672-A065B3DD-8BB6-495F-8806-64C5F9978015 Q37386143-8DD536A1-B655-4BA3-9A33-5309DF918DB5 Q37590895-F94381DE-B94E-4A7A-910A-0BECC09918E3 Q37626382-8912FE88-F528-403D-87FC-E15EAEEE1A3F Q37730221-A292AF8D-5694-4025-9F21-63214FE1DCB2 Q38369228-3CECA277-0C36-4928-9864-C0355C4A06F8 Q38547279-51BE97F0-6995-48C8-AF04-2E048559CF2C Q38600277-948C7E98-EF03-4F3D-A1C6-4C7296432001 Q38771098-AE49C554-15F0-42A4-86D7-2A7500047C74 Q38810544-B10CAAA3-EA46-4184-88BD-B243711CD9B4 Q39066716-240E0431-2FC8-4680-8071-276569D44407 Q39155261-9FFDD7EF-A291-4D83-A86A-5CA129C94666 Q39215443-1FBD7875-81CF-4A21-B304-CD0A4E6243DD Q42108768-2171CB95-9135-4AA3-AC39-4B5266C61A4F Q42315307-90A3D7D5-1BD6-4906-A7C1-D96BDF03F1B7 Q42335462-E30B56BA-3A22-442D-8E91-C7574D1193B1 Q43132552-F6E9E2FF-0D96-40AB-AFA7-4B49D6420645 Q46707533-11BF8D12-CE88-4A49-893F-AB7988FA66CE Q47587631-0047B4F7-6BB9-4C9B-8039-D3710364FAFD Q47926474-6CDD9F02-0A8B-4159-8EC8-01D81BE8D41F Q48460611-2A89A231-BB8A-4DC7-85D6-7BC98ED5C2BF

P2860

Development of positron emission tomography β-amyloid plaque imaging agents

http://www.wikidata.org/entity/Q27012742

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Development of positron emission tomography β-amyloid plaque imaging agents

@ast

Development of positron emission tomography β-amyloid plaque imaging agents

@en

Development of positron emission tomography β-amyloid plaque imaging agents

@nl

type

label

Development of positron emission tomography β-amyloid plaque imaging agents

@ast

Development of positron emission tomography β-amyloid plaque imaging agents

@en

Development of positron emission tomography β-amyloid plaque imaging agents

@nl

prefLabel

Development of positron emission tomography β-amyloid plaque imaging agents

@ast

Development of positron emission tomography β-amyloid plaque imaging agents

@en

Development of positron emission tomography β-amyloid plaque imaging agents

@nl

P1433

Q27012742-D15746D5-D6DA-4532-B2B5-A513D58DA71B

P1476

Q27012742-EB237CAC-CCD0-4D09-ABB2-DD48DC359CD3

P2093

Q27012742-3FE84D08-425E-4D17-A115-493EB1E6D5C1

Q27012742-6908D38A-AC39-4D64-B183-BDD3BFBCA25B

Q27012742-E6C27C2F-427B-493B-BF52-3D5B43D80FD9

P2860

Q27012742-00DF31EE-3D35-43D8-A58C-37B8C0FAF36B

Q27012742-05BE3E8A-0F67-4418-88F1-388BA843AC93

Q27012742-094D4102-0AB1-4987-A6EA-DF9DB05D1338

Q27012742-0D5D4CED-90DE-4830-88E9-90CD6B627406

Q27012742-0DAF5430-E7EE-4068-8E22-73F5F93D700B

Q27012742-0F99A0DD-423C-410B-9BF0-FB3AF9A4C292

Q27012742-114586FA-A6E9-45C8-B40F-6F08747F2B94

Q27012742-171BC560-4F8F-4AEC-ADA6-B18F649A377E

Q27012742-1C935885-C792-4C87-9587-0F22D83CA3B5

Q27012742-2419A5A2-A280-4DE8-9CFB-F97F746C57E5

P304

Q27012742-58E89737-0513-456D-A6FE-280AFCE85CFA

P31

Q27012742-A45FAC38-6AA6-42CB-9382-33F1DAD92DCB

P3181

Q27012742-EA72A14F-C564-481F-86E5-23BB60993436

P356

Q27012742-8F3BE0E9-BFD7-40BA-95FD-13C711C9AF86

P407

Q27012742-485D1D0D-5497-4A67-8B09-A259258E3C0C

P433

Q27012742-5421508A-A10B-4CC2-BC53-2699456487CF

P478

Q27012742-481FDA30-8F88-4EA7-B972-ED92141DFBB9

P50

Q27012742-601532A1-76D0-40CC-8BBF-8044A73DA5E3

P577

Q27012742-A9FF02E4-B277-479C-BF79-5D406ADA98C9

P5875

Q27012742-96AE9AE9-AA9F-4B94-8355-D6D9A094F675

P698

Q27012742-2C5D098D-0131-440D-8AEC-68A236059E5C

P932

Q27012742-8C2075E9-C151-4729-B555-48128E465838

P3181

P356

J.SEMNUCLMED.2012.07.001

P1433

Seminars in Nuclear Medicine

P1476

Development of positron emission tomography β-amyloid plaque imaging agents

@en

P2093

Brian J. Lopresti

http://www.w3.org/2001/XMLSchema#string

Chester A. Mathis

http://www.w3.org/2001/XMLSchema#string

N. Scott Mason

http://www.w3.org/2001/XMLSchema#string

P2860

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

Testing the right target and right drug at the right stage

Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain.

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology.

P304

423-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2698778

http://www.w3.org/2001/XMLSchema#string

P356

10.1053/J.SEMNUCLMED.2012.07.001

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

William E. Klunk

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

231741131

http://www.w3.org/2001/XMLSchema#string

P698

23026364

http://www.w3.org/2001/XMLSchema#string

P932

3520098

http://www.w3.org/2001/XMLSchema#string